Friday 3rd May 2024 |
Text too small? |
AFT Pharmaceuticals to announce full year results on Thursday May 23 2024
AFT Pharmaceuticals (NZX: AFT , ASX: AFP) announced today that it intends to release its full year FY2024, ended March 31 2024, results on Thursday May 23 2024. The release will be issued at around 09:00 am (NZT) on the NZX and ASX.
Following the release, management will present via webinar at 10:30 am (NZT). Presentation material will be available on the company’s website AFT, the NZX website NZX and the ASX website ASX.
To participate in the upcoming earnings webinar, please pre-register with the provided link, below. Webinar details will be provided upon completion of your registration.
Registration Link: AFT results presentation FY2024
For and on behalf of AFT Pharmaceuticals Limited, Malcolm Tubby, CFO.
For more information:
Investors Media
Malcolm Tubby Richard Inder
CFO, AFT Pharmaceuticals Ltd The Project
Phone: +64 9 488 0232 Phone: 021 645 643
Email: malcolm@aftpharm.com Email: richard@theproject.co.nz
About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to the rest of the world. For more information: aftpharm.com
AFT Pharmaceuticals to announce full year results on Thursday May 23 2024
No comments yet
Second St John withdrawal of labour takes effect tomorrow with further strikes likely
Sanford Appoints Independent Director
CRP ADVISES CLOSURE OF SHARE OFFER TO EXISTING INVESTOR
Devon Funds Morning Note - 14 August 2024
OCR 5.25% - Monetary restraint tempered as inflation converges on target
Consumers still need due diligence as new deposit takers emerge.
Woolworths strike: staff asked to dress up in Disney costumes for a week on their own dollar
Turners Invests in Quashed Online Insurance Platform
PGW Reports on Challenging Year
Arvida Announces Executive Team Changes